2 tracked superinvestors hold IONIS PHARMACEUTICALS INC (IONS), worth $1.1B combined, led by Steve Wymer. Smart money is accumulating IONS as of the latest 13F filings.
Current price
$58.09
-2.1%
1Y
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting…
Market cap
$12.4B
P/E
-37.45
Div yield
0.0%
Revenue YoY
33.9%
Analyst target
$91
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
2
tracked 13F / N-PORT funds
Combined value
$1.1B
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating IONS: 1 funds added or opened versus 0 trimming.
IONIS PHARMACEUTICALS INC (IONS) appears mainly in diversified and quant books here (2 funds, $1.1B combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Steve Wymer at 0.7% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 1 added and 0 trimmed, a net add.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.7% | $648M | |
| Added | 0.4% | $496M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
6 insiders filed SEC Form 144 for $13M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Bennett C Frank | Officer | 67,386 | $6M | 2026-07-07 |
| Diaz Allene M. | Director | 10,111 | $864K | 2026-07-07 |
| Klein Joseph Iii | Director | 11,518 | $910K | 2026-07-01 |
| Schneider Eugene | Officer | 47,884 | $4M | 2026-06-26 |
| Swayze Eric | Officer | 10,602 | $839K | 2026-06-25 |
| Berthelsen Spencer R | Director | 8,000 | $588K | 2026-06-15 |
Which superinvestors own IONS?
2 tracked funds hold IONIS PHARMACEUTICALS INC (IONS), the largest being Steve Wymer (Fidelity Growth Company) at 0.7% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling IONS?
In the most recent 13F quarter, 1 tracked fund added or opened IONS and 0 trimmed it.
How much IONS do tracked funds hold?
Combined disclosed long exposure to IONS across tracked superinvestors is $1.1B as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.